Europe
5 May 2026 John Ward, vice president and associate general counsel of trademarks at Moderna, chats with Tom Phillips at INTA 2026.
30 April 2026
21 April 2026
16 April 2026
Latest Features
Europe
Europe’s latest patent fee increases are modest at the EPO but include a rare steep hike in the UK, forcing applicants to reassess filing routes, portfolio value, and long-term cost strategies, say James Bell and Yelena Morozova.
Europe
After an overwhelmingly positive Supreme Court ruling for companies working in AI, Rachel Free of CMS outlines the necessary practical steps for patent holders—including enforcement of the ‘black box’ tech, the ruling’s influence on the UPC, and how to manage related applications.
Europe
Traceability and transparency of training practices, and the value of bespoke tool, are among the key AI trends that will be shaped by legal and regulatory developments in 2026, write experts from Rouse.
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Europe
In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.
Europe
It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.
More News
15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.
13 April 2026 New report finds that just 13% of IP-owning firms have sought financing through their assets, with billions in potential funding left untapped, as structural barriers persist.
9 April 2026 In light of Emotional Perception AI, the UKIPO has rewritten the rules for “mixed inventions". Matt Jefferies and Eric McNeil of Marks & Clerk explore what this pivot means for applicants protecting their AI technology.
8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.
7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.
2 April 2026 Two of Europe’s most important IP offices have implemented fee increases this month, with some long-standing UK charges, dating back to the late 1990s, finally seeing a rise.
2 April 2026 A Lisbon judge rejects a bid to strike out the case over a drafting issue, offering insight into the court’s high bar for early dismissal.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox